These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 2166055

  • 1. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.
    Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD.
    J Cell Biol; 1990 Aug; 111(2):783-92. PubMed ID: 2166055
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV, Andreasen P, Ragno P, Mayer M, Danø K, Blasi F.
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
    Ellis V, Wun TC, Behrendt N, Rønne E, Danø K.
    J Biol Chem; 1990 Jun 15; 265(17):9904-8. PubMed ID: 2161846
    [Abstract] [Full Text] [Related]

  • 6. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.
    Olson D, Pöllänen J, Høyer-Hansen G, Rønne E, Sakaguchi K, Wun TC, Appella E, Danø K, Blasi F.
    J Biol Chem; 1992 May 05; 267(13):9129-33. PubMed ID: 1315748
    [Abstract] [Full Text] [Related]

  • 7. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.
    McNeill H, Jensen PJ.
    Cell Regul; 1990 Oct 05; 1(11):843-52. PubMed ID: 1965151
    [Abstract] [Full Text] [Related]

  • 8. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM, Strickland S.
    J Cell Physiol; 1997 May 05; 171(2):217-25. PubMed ID: 9130470
    [Abstract] [Full Text] [Related]

  • 9. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ, Krikun G, Papp C, Aigner S, Schatz F.
    J Clin Endocrinol Metab; 1995 Apr 05; 80(4):1100-5. PubMed ID: 7714076
    [Abstract] [Full Text] [Related]

  • 10. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ, Lee SW, Dichek DA, Ellis V.
    J Pept Sci; 2000 Sep 05; 6(9):432-9. PubMed ID: 11016879
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
    Reinartz J, Link J, Todd RF, Kramer MD.
    Exp Cell Res; 1994 Oct 05; 214(2):486-98. PubMed ID: 7925643
    [Abstract] [Full Text] [Related]

  • 14. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ, Marshall JM, Cottingham IR, Steven J, Berry SJ, Cederholm-Williams SA, Goodey AR, Courtney M.
    Eur J Biochem; 1992 Jul 01; 207(1):177-83. PubMed ID: 1321039
    [Abstract] [Full Text] [Related]

  • 15. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
    Ragno P, Montuori N, Rossi G.
    Eur J Biochem; 1995 Oct 15; 233(2):514-9. PubMed ID: 7588796
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
    Baker MS, Bleakley P, Woodrow GC, Doe WF.
    Cancer Res; 1990 Aug 01; 50(15):4676-84. PubMed ID: 2114945
    [Abstract] [Full Text] [Related]

  • 17. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 18. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.
    Waltz DA, Sailor LZ, Chapman HA.
    J Clin Invest; 1993 Apr 01; 91(4):1541-52. PubMed ID: 8386190
    [Abstract] [Full Text] [Related]

  • 19. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
    Behrendt N, List K, Andreasen PA, Danø K.
    Biochem J; 2003 Apr 15; 371(Pt 2):277-87. PubMed ID: 12534347
    [Abstract] [Full Text] [Related]

  • 20. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
    Lundgren CH, Sawa H, Sobel BE, Fujii S.
    Circulation; 1994 Oct 15; 90(4):1927-34. PubMed ID: 7923681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.